IDEXX LaboratoriesFRA:IX1 -0.19%96 ROA % is 33.28% as of Mar. 2026, which is 25% above its 10-year median of 26.65. GuruFocus rates FRA:IX1 with a GF Score™ of 96/100 and a GF Value™ of €544.17 (Modestly Undervalued). Among 215 Medical Diagnostics & Research companies, IDEXX Laboratories ranks better than 96.74% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. IDEXX Laboratories's annualizedNet Income for the quarter that ended in Mar. 2026 was €963 Mil.
IDEXX Laboratories's average Total Assets over the quarter that ended in Mar. 2026 was €2,895 Mil. Therefore, IDEXX Laboratories's annualized ROA % for the quarter that ended in Mar. 2026 was 33.28%.
The historical rank and industry rank for IDEXX Laboratories's ROA % or its related term are showing as below:
FRA:IX1'
s ROA % Range Over the Past 10 Years
Min: 14.77 Med: 26.65 Max: 32.86
Current: 32.86
During the past 13 years, IDEXX Laboratories's highest ROA % was 32.86%. The lowest was 14.77%. And the median was 26.65%.
FRA:IX1's ROA % is ranked better than 96.74% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.87
vs FRA:IX1: 32.86
IDEXX Laboratories (FRA:IX1) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
IDEXX Laboratories ROA % Related Terms
IDEXX Laboratories ROA % Historical Data
* Premium members only.
The historical data trend for IDEXX Laboratories's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, IDEXX Laboratories's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDEXX Laboratories ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's ROA % distribution charts can be found below:
* The bar in red indicates where IDEXX Laboratories's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
IDEXX Laboratories (FRA:IX1) has a ROA % of 33.28% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on IDEXX Laboratories and its competitors. This is 25% above median its historical median of 26.65. Over the past decade, IDEXX Laboratories' ROA % has ranged from 14.77 to 32.86. According to the industry distribution chart, IDEXX Laboratories ranks #7 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 3.3%.
Is IDEXX Laboratories' ROA % too high?
IDEXX Laboratories' current ROA % of 33.28% is 25% above median its 10-year median of 26.65. Over the past 10 years, this metric has ranged from a low of 14.77 to a high of 32.86. Based on the distribution chart, IDEXX Laboratories ranks #7 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDEXX Laboratories has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' ROA % compare to A and WAT?
According to the Medical Diagnostics & Research industry distribution chart, IDEXX Laboratories ranks #7 out of 215 companies for ROA %. This places IDEXX Laboratories in the top 3% of its industry — outperforming the majority of peers. Historically, IDEXX Laboratories' own ROA % has ranged from 14.77 to 32.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current ROA % is 33.28%, which is 25% above median its own 10-year median of 26.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (FRA:IX1) is currently considered Modestly Undervalued. The stock's GF Value™ is €544.17, compared to a current price of €473.80 — trading 12.9% below its estimated fair value. The current ROA % is 33.28%, which is 25% above median its 10-year median of 26.65. IDEXX Laboratories' overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For IDEXX Laboratories (FRA:IX1), the current ROA % is 33.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDEXX Laboratories (FRA:IX1) Overvalued in 2026?
Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued.
The current stock price of €473.80 is trading 12.9% below its estimated GF Value™ of €544.17.
GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.
Key valuation signals for FRA:IX1:
ROA %: 33.28% (25% above median its 10-year median of 26.65)
GF Value™: €544.17 vs. price of €473.80 (12.9% below fair value)
No single metric tells the full story. See the FRA:IX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
96GF Score
Get the complete analysis for FRA:IX1
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IX1 has been successfully added to your 
